Informed consent in the psychosis prodrome: ethical, procedural and cultural considerations

Philosophy, Ethics, and Humanities in Medicine

Robert K Heinssen²  Sarah E Morris¹ 

[1] Division of Adult Translational Research, National Institute of Mental Health, 6001 Executive Blvd, North Bethesda, MD 20892, USA;Division of Services and Intervention Research, National Institute of Mental Health, 6001 Executive Blvd, North Bethesda, MD 20892, USA

关键词: Culture;    International;    Schizophrenia;    Psychosis;    Prodrome;    Informed consent;    Ethics;   

Others  :  1132042
DOI  :  10.1186/1747-5341-9-19

 received in 2014-02-03, accepted in 2014-10-24,  发布年份 2014

【 摘 要 】

Research focused on the prodromal period prior to the onset of psychosis is essential for the further development of strategies for early detection, early intervention, and disease pre-emption. Such efforts necessarily require the enrollment of individuals who are at risk of psychosis but have not yet developed a psychotic illness into research and treatment protocols. This work is becoming increasingly internationalized, which warrants special consideration of cultural differences in conceptualization of mental illness and international differences in health care practices and rights regarding research participation. The process of identifying and requesting informed consent from individuals at elevated risk for psychosis requires thoughtful communication about illness risk and often involves the participation of family members. Empirical studies of risk reasoning and decisional capacity in young people and individuals with psychosis suggest that most individuals who are at-risk for psychosis can adequately provide informed consent; however ongoing improvements to tools and procedures are important to ensure that this work proceeds with maximal consideration of relevant ethical issues. This review provides a discussion of these issues in the context of international research efforts.

【 授权许可】

   
2014 Morris and Heinssen; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992, 149:1183-1188.
• [2]Harrigan SM, McGorry PD, Krstev H: Does treatment delay in first-episode psychosis really matter? Psychol Med 2003, 33:97-110.
• [3]Crow TJ, MacMillan JF, Johnson AL, Johnstone EC: A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986, 148:120-127.
• [4]Benatar SR, Fleischer TE: Ethical issues in research in low-income countries [Leading Article]. Int J Tuberc Lung Dis 2007, 11:617-623.
• [5]Yung AR, Yuen H, Mcgorry PD, Phillips LJ, Kelly D, Dell’olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J: Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry 2005, 39:964-971.
• [6]Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW: Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003, 29:703-715.
• [7]Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton M, Barale F, Caverzasi E, McGuire P: Predicting psychosis: a meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012, 69:1-10.
• [8]Fusar-Poli P, Bechdolf A, Taylor M, Bonoldi I, Carpenter W, Yung A, McGuire P: At risk for schizophrenic or affective psychosis? A meta-analysis of ICD/DSM diagnostic outcomes in individuals at high clinical risk. Schizophr Bull 2012. in press
• [9]Fusar-Poli P, Deste G, Smieskova R, Barlati G, Yung AR, Howes O, Stieglitz R, McGuire P, Borgwardt S: Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 2012. in press
• [10]Fusar-Poli P, Borgwardt S, Crescini A, D’Este G, Kempton M, Lawrie S, Guire PM, Sacchetti E: Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev 2011, 35:1175-1185.
• [11]Fusar-Poli P, Radua J, McGuire P, Borgwardt S: Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr Bull 2011. Epub
• [12]Fusar-Poli P, Perez J, Broome M, Borgwardt S, Placentino A, Caverzasi E, Cortesi M, Veggiotti P, Politi P, Barale F, McGuire P: Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev 2007, 31:465-484.
• [13]Crossley NA, Mechelli A, Fusar-Poli P, Broome MR, Matthiasson P, Johns LC, Bramon E, Valmaggia L, Williams SC, McGuire PK: Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp 2009, 30:4129-4137.
• [14]Fusar-Poli P, Stone J, Broome M, Valli I, Mechelli A, McLean M, Lythgoe D, O’Gorman R, Barker G, McGuire P: Thalamic glutamate levels predicts cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry 2011. Epub
• [15]Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Grasby PM, McGuire PK: Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 2010, 67:683-691.
• [16]Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Montgomery AJ, Grasby PM, McGuire P: Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 2011, 16:67-75.
• [17]Fusar-Poli P, Meyer-Lindenberg A: Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [18F]/[11C] DOPA PET studies. Schizophr Bull 2012. Epub
• [18]Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz R: Neuroimaging predictors of transition to psychosis—a systematic review and meta-analysis. Neurosci Biobehav Rev 2010, 34:1207-1222.
• [19]Preti A, Cella M: Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res 2010, 123:30-36.
• [20]Addington J, Heinssen R: Prediction and prevention of psychosis in Youth at clinical high risk. Annu Rev Clin Psychol 2012, 8:269-289.
• [21]Mamah D, Mbwayo A, Mutiso V, Barch DM, Constantino JN, Nsofor T, Khasakhala L, Ndetei DM: A survey of psychosis risk symptoms in Kenya. Compr Psychiatry 2012, 53:516-524.
• [22]Fresan A, Apiquian R, Ulloa RE, Nicolini H: Reliability study of the translation into Spanish of the PRIME screen questionnaire for prodromic symptoms. Actas Esp Psiquiatr 2007, 35:368-371.
• [23]Jung MH, Jang JH, Kang D-H, Choi J-S, Shin NY, Kim HS, An SK, Shin M-S, Kwon JS: The reliability and validity of the Korean version of the structured interview for prodromal syndrome. Psychiatry Investig 2010, 7:257-263.
• [24]Kobayashi H, Nozaki S, Mizuno M: Reliability of the structured interview of prodromal syndromes Japanese version (SIPS-J). JPN J Soc Psychiatry 2006, 15:168-174.
• [25]Owoso A, Ndetei DM, Mbwayo AW, Mutiso VN, Khasakhala LI, Mamah D: Validation of a modified version of the PRIME screen for psychosis-risk symptoms in a non-clinical Kenyan youth sample. Compr Psychiatry 2014, 55:380-387.
• [26]Kobayashi H, Nemoto T, Koshikawa H, Osono Y, Yamazawa R, Murakami M, Kashima H, Mizuno M: A self-reported instrument for prodromal symptoms of psychosis: testing the clinical validity of the PRIME Screen—Revised (PS-R) in a Japanese population. Schizophr Res 2008, 106:356-362.
• [27]Cornblatt BA, Carrion RE, Addington J, Seidman L, Walker EF, Cannon TD, Cadenhead KS, McGlashan TH, Perkins DO, Tsuang MT, Woods SW, Heinssen R, Lencz T: Risk factors for psychosis: impaired social and role functioning. Schizophr Bull 2012, 38:1247-1257.
• [28]Thompson AD, Bartholomeusz C, Yung AR: Social cognition deficits and the ‘ultra high risk’ for psychosis population: a review of literature. Early Interv Psychiatry 2011, 5:192-202.
• [29]Cullen K, Guimaraes A, Wozniak J, Anjum A, Schulz S, White T: Trajectories of social withdrawal and cognitive decline in the schizophrenia prodrome. Clin Schizophr Relat Psychoses 2011, 4:229-238.
• [30]Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, Keefe RSE, Heinssen R, Cornblatt BA, for the North American Prodrome Longitudinal Study Group: Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 2010, 67:578-588.
• [31]Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E: The Schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull 2003, 29:633-651.
• [32]Walker EF, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Woods SW, Heinssen R: The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res 2009, 115:50-57.
• [33]Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P: Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012, 69:220-229.
• [34]Addington J, Francey SM, Morrison A: Working with People at High Risk of Developing Psychosis: A Treatment Handbook. Chichester: Wiley; 2006.
• [35]Schaffner K, McGorry P: Preventing severe mental illnesses—new prospects and ethical challenges. Schizophr Res 2001, 51:3.
• [36]Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R: At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 2011, 168:800-805.
• [37]Rossler W, Hengartner MP, Ajdacic-Gross V, Haker H, Gamma A, Angst J: Sub-clinical psychosis symptoms in young adults are risk factors for subsequent common mental disorders. Schizophr Res 2011, 131:18-23.
• [38]Haroun N, Dunn L, Haroun A, Cadenhead KS: Risk and protection in Prodromal Schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull 2006, 32:166-178.
• [39]Heinssen RK, Perkins DO, Appelbaum PS, Fenton WS: Informed consent in early psychosis research: national institute of mental health workshop, November 15, 2000. Schizophr Bull 2001, 27:571-583.
• [40]Schouten BC, Meeuwesen L: Cultural differences in medical communication: a review of the literature. Patient Educ Couns 2006, 64:21-34.
• [41]Hussain-Gambles M, Leese B, Atkin K, Brown J, Mason S: Involving South Asian patients in clinical trials. Health Technol Assess 2004, 8:124.
• [42]Limkakeng A, Phadtare A, Shah J, Vaghasia M, Wei DY, Shah A, Pertrobon R: Willingness to participate in clinical trials among patients of chinese heritage: a meta-synthesis. PLoS One 2013, 8:e51328.
• [43]Leflar RB: The cautious acceptance of informed consent in Japan. Med Law 1997, 16:705-720.
• [44]Piwowarczyk L, Bishop H, Yusuf A, Mudymba F, Raj A: Congolese and Somali beliefs about mental health services. J Nerv Ment Dis 2014, 202:209-216.
• [45]Mamah D, Striley CW, Ndetei DM, Mbwayo AW, Mutiso VN, Khasakhala LI, Cottler LB: Knowledge of psychiatric terms and concepts among Kenyan youth: analysis of focus group discussions. Transcult Psychiatry 2013, 50:515-531.
• [46]Redko C: Religious construction of a first episode of psychosis in Urban Brazil. Transcult Psychiatry 2003, 40:507-530.
• [47]Saravanan B, Jacob KS, Deepak MG, Prince M, David A, Bhugra D: Perceptions about psychosis and psychiatric services: a qualitative study from Vellore, India. Soc Psychiat Epidemiol 2008, 43:231-238.
• [48]Kitamura F, Tomoda A, Tsukada K, Tanaka M, Kawakami I, Mishima S, Kitamura T: Method for assessment of competency to consent in the mentally ill: rationale, development, and comparison with the medically ill. Int J Law Psychiatry 1998, 21:223-244.
• [49]Seo MK, Kim SH, Rhee M: Developing a tool to assess competency to consent to psychiatric hospitalization (KATOC): Reliability and validity. Psychiatry Investig 2011, 8:39-48.
• [50]Berg J, Appelbaum PS: Subjects’ Capacity to Consent to Neurobiological Research. In Ethics in Psychiatric Research: A Resource Manual for Human Subjects Protection. Edited by Pinkus H, Lieberman J, Ferris S. Washington, DC: American Psychiatric Association; 1999:81-106.
• [51]Appelbaum PS, Roth LH: Competency to consent to research: a psychiatric overview. Arch Gen Psychiatry 1982, 39:951-958.
• [52]Benson PR, Roth LH, Winslade WJ: Informed consent in psychiatric research: preliminary findings from an ongoing investigation. Soc Sci Med 1985, 20:1331-1341.
• [53]Edward DS: The capacity to consent to treatment and research: a review of standardized assessment tools. Clin Psychol Rev 2005, 25:954-974.
• [54]Dunn LB, Nowrangi MA, Palmer BW, Jeste DV, Saks ER: Assessing decisional capacity for clinical research or treatment: a review of instruments. Am J Psychiatry 2006, 163:1323-1334.
• [55]Dunn LB, Palmer BW, Appelbaum PS, Saks ER, Aarons GA, Jeste DV: Prevalence and correlates of adequate performance on a measure of abilities related to decisional capacity: differences among three standards for the MacCAT-CR in patients with schizophrenia. Schizophr Res 2007, 89:110-118.
• [56]De Marco MC, Sani G, Manfredi G, Pacchiarotti I, Savoja V, Balbi A, Mazzarini L, Borriello A, Kotzalidis GD, Tatarelli R, Girardi P, Ferracuti S: Assessment of the capacity to express informed consent for organ donation in patients with Schizophrenia. J Forensic Sci 2010, 55:669-676.
• [57]Dunn LB, Candilis PJ, Roberts LW: Emerging empirical evidence on the ethics of Schizophrenia research. Schizophr Bull 2006, 32:47-68.
• [58]Moser D, Schultz S, Arndt S, Benjamin M, Fleming F, Brems C, Paulsen J, Appelbaum PS, Andreasen NC: Capacity to provide informed consent for participation in schizophrenia and HIV research. Am J Psychiatry 2002, 159:1201-1207.
• [59]Candilis PJ, Fletcher KE, Geppert CMA, Lidz CW, Appelbaum PS: A direct comparison of research decision-making capacity: Schizophrenia/schizoaffective, medically ill, and non-ill subjects. Schizophr Res 2008, 99:350-358.
• [60]Carpenter WT, Gold JM, Lahti AC, Queern CA, Conley RR, Bartko JJ, Kovnick J, Appelbaum PS: Decisional capacity for informed consent in Schizophrenia research. Arch Gen Psychiatry 2000, 57:533-538.
• [61]Jeste DV, Depp CA, Palmer BW: Magnitude of impairment in decisional capacity in people with Schizophrenia compared to normal subjects: an overview. Schizophr Bull 2006, 32:121-128.
• [62]McGlashan TH, Miller TJ, Woods SW: Pre-onset detection and intervention research in Schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull 2001, 27:563-570.
• [63]Dunn LB, Jeste DV: Enhancing informed consent for research and treatment. Neuropsychopharmacology 2001, 24:595-607.
• [64]Bourque F, van der Ven E, Fusar-Poli P, Malla A: Immigration, social environment and onsent of psychotic disorders. Curr Pharm Des 2012, 18:518-526.
• [65]Douglas A, Bhopal R, Bhopal R, Forbes J, Gill J, Lawton J, McKnight J, Murray G, Sattar N, Sharma A, Tuomilehto J, Wallia S, Wild S, Sheikh A: Recruiting South Asians to a lifestyle intervention trial: experiences and lessons from PODOSA (Prevention of Diabetes & Obesity in South Asians). Trials 2011, 12:220.
• [66]Zhang T, Li H, Woodberry KA, Seidman LJ, Zheng L, Li H, Zhao S, Tang Y, Guo Q, Lu X, Zhuo K, Qian Z, Chow A, Li C, Jiang K, Xiao Z, Wang J: Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study. Schizophr Res 2014, 152:391-399.
• [67]Chen HH, Phillips MR, Cheng H, Chen XD, Fralick D, Zhang YE, Liu M, Huang J, Bueber M: Mental health law of the People’s Republic of China (English translation with annotations). Shanghai Arch Psychiatry 2012, 24:305-321.
• [68]Phillips MR, Chen H, Diesfeld K, Xie B, Cheng HG, Mellsop G, Liu X: China’s new mental health law: reframing involuntary treatment. Am J Psychiatry 2013, 170:588-591.
• [69]Di X, Cheng HG: Competence of consent and associated factors among inpatients of schizophrenia in Changsha, China. Schizophr Res 2013, 150:325-326.
• [70]Owen GS, Richardson G, David AS, Szmukler G, Hayward P, Hotopf M: Mental capacity to make decisions on treatment in people admitted to psychiatric hospitals: cross sectional study. BMJ 2008, 337:a448.
• [71]Scott ES, Reppucci ND, Woolard JL: Evaluating adolescent decision making in legal contexts. Law Hum Behav 1995, 19:221-244.
• [72]Miller VA, Drotar D, Kodish E: Children’s competence for assent and consent: a review of empirical findings. Ethics Behav 2004, 14:255-295.
• [73]Io M: The Ethical Conduct of Clinical Research Involving Children. Washington, D.C.: The National Academies Press; 2004.
• [74]Heerey EA, Robinson BM, McMahon RP, Gold JM: Delay discounting in schizophrenia. Cogn Neuropsychiatry 2007, 12:213-221.
• [75]Heerey EA, Matveeva TM, Gold JM: Imagining the future: degraded representations of future rewards and events in schizophrenia. J Abnorm Psychol 2011, 120:483-489.
• [76]Kester HM, Sevy S, Yechiam E, Burdick KE, Cervellione KL, Kumra S: Decision-making impairments in adolescents with early-onset schizophrenia. Schizophr Res 2006, 85:113-123.
• [77]Burns JK: Pathways from cannabis to psychosis: a review of the evidence. Front Psychiatry 2013, 4:a128.
• [78]van Winkel R, Kuepper R: Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis. Annu Rev Clin Psychol 2014., 10epub ahead of print
• [79]Mata I, Rodríguez-Sánchez JM, Pelayo-Terán JM, Pérez-Iglesias R, González-Blanch C, Ramírez-Bonilla M, Martínez-García O, Vázquez-Barquero JL, Crespo-Facorro B: Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychol Med 2008, 38:1257-1266.
• [80]Chen H, Kramer E, Chen T, Chung H: Engaging Asian Americans for mental health research: challenges and solutions. J Immigrant Health 2005, 7:109-118.
• [81]Sabbag S, Twamley EM, Vella L, Heaton RK, Patterson TL, Harvey PD: Assessing everyday functioning in schizophrenia: not all informants seem equally informative. Schizophr Res 2011, 131:250-255.
• [82]Kline E, Thompson E, Schimunek C, Reeves G, Bussell K, Pitts SC, Schiffman J: Parent–adolescent agreement on psychosis risk symptoms. Schizophr Res 2013, 147:147-152.
• [83]Gerson R, Wong C, Davidson L, Malaspina D, McGlashan T, Corcoran C: Self-reported coping strategies in families of patients in early stages of psychotic disorder: an exploratory study. Early Interv Psychiatry 2011, 5:76-80.
• [84]Scherer DG: The capacities of minors to exercise voluntariness in medical treatment decisions. Law Hum Behav 1991, 15:431-449.
• [85]O’Brien MP, Zinberg JL, Bearden CE, Lopez SR, Kopelowicz A, Daley M, Cannon TD: Parent attitudes and parent adolescent interaction in families of youth at risk for psychosis and with recent-onset psychotic symptoms. Early Interv Psychiatry 2008, 2:268-276.
• [86]Fortune DG, Smith JV, Garvey K: Perceptions of psychosis, coping, appraisals, and psychological distress in the relatives of patients with schizophrenia: an exploration using self-regulation theory. Br J Clin Psychol 2005, 44:319-331.
• [87]Lauber C, Rossler W: Relatives and their attitude to early detection of schizophrenic psychosis. Psychiatr Bull R Coll Psychiatr 2003, 27:134-136.
• [88]Wong C, Davidson L, Anglin D, Link B, Gerson R, Malaspina D, McGlashan T, Corcoran C: Stigma in families of individuals in early stages of psychotic illness: family stigma and early psychosis. Early Interv Psychiatry 2009, 3:108-115.
• [89]Li H, Friedman-Yahoobian M, Min G, Granato AG, Seidman LJ: Working with Asian American youth at clinical high risk for psychosis. J Nerv Ment Dis 2013, 201:484-489.
• [90]Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RSE, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA: Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study. Schizophr Res 2011, 130:47-52.
• [91]Addington J, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Addington JA, Cannon TD: North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. Schizophr Res 2012, 142:77-82.
• [92]McGorry PD, Yung A, Phillips L: Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 2001, 51:17-29.
• [93]Appelbaum PS: Decisional capacity of patients with Schizophrenia to consent to research: taking stock. Schizophr Bull 2006, 32:22-25.
• [94]Muroff JR, Hoerauf SL, Kim SYH: Is psychiatric research stigmatized? An experimental survey of the public. Schizophr Bull 2006, 32:129-136.